i&i Prague announces its first exit: DIANA Biotechnologies
21.2.2022Prague, 21 February 2022 – BTND a.s. has completed the buyout of DIANA Biotechnologies from the portfolio of biotech incubator i&i Prague. For i&i Prague, the transaction opens up new…
CasInvent Pharma receives the Neuron Award for excellent Technology Transfer
1.10.2021The laureates of the prestigious Neuron Awards in 2021 have been announced. Since 2009, the Neuron Endowment Fund has been rewarding the first-class Czech researchers for their…
i&i Prague supports the innovative start-up PEP-Therapy in their extension of the Series-A financing, totalling €5.4 million to progress the clinical development of the lead candidate PEP-010
10.9.2021PEP-Therapy, a biotechnology company developing cell penetrating peptides as targeted therapies for the treatment of cancers, announced today that it raised an additional €2.6 million ($3 million) in an extension…
Licensing agreement for a novel SARS Cov-2 virus neutralization antibody test was signed
8.9.2021We are very happy to inform you that i&i Prague has participated on a development of novel in vitro diagnostics test measuring virus neutralization antibodies against SARS Cov-2 in human…
Enantis, a Masaryk University spin-off company, concluded a license agreement for the production of stabilised growth factor FGF2.
29.1.2021After months of negotiations, we are delighted to announce that Enantis, one of i&i Prague´s first supported start-ups, has entered into a…
LAM-X, a.s. won the 2020 EIT Health #MedTech Bootcamp final #Pitch Event
18.1.2021i&i Prague supported start-up, LAM-X, a.s., become a winner of the 2020 EIT Health…
Learn more about CasInvent Pharma, a.s., an university spin-off developing leukaemia treatment!
6.1.2021Don´t miss this interesting report on ČT24 about the newest Masaryk University spin-off: CasInvent Pharma, a.s.! With the…
CasInvent Pharma, a New University Spin-Off Focused on Developing Cancer Drugs Established with Help of i&i Prague!
16.12.2020A new spin-off company, CasInvent Pharma, a.s., has been established by Masaryk University (MU) in cooperation with its investment partner, i&i Prague, s.r.o. (Ltd), in order to facilitate further development…
PerioTrap Pharmaceuticals, an i&i Prague Supported Start-up, Raises €3M Seed Round to Develop Selective Anti-infectives to Tackle Periodontitis
20.11.2020Although periodontitis represents a widespread infectious disease affecting around 30% of the global population, there is no effective treatment for patients available, yet. PerioTrap Pharmaceuticals, a Fraunhofer IZI spin-off, has…
Dracen Pharmaceuticals Announces the Initiation of First-in-human Study of DRP-104 in Adult Patients With Advanced Solid Tumors!
13.10.2020Pavel Majer, ÚOCHB Dracen Pharmaceuticals, Inc. has announced the start of a clinical trial of DRP-104, an anti-cancer substance developed by the team of Pavel Majer at IOCB Prague…